Effectiveness of Butylphthalide on Dynamic Cerebral Autoregulation in Patients With Acute Ischemic Stroke.

PHASE4CompletedINTERVENTIONAL
Enrollment

99

Participants

Timeline

Start Date

February 28, 2018

Primary Completion Date

March 25, 2022

Study Completion Date

May 25, 2022

Conditions
Acute Ischemic Stroke
Interventions
DRUG

butylphthalide(NBP)

Standard medical care is in accordance with China Guideline for the diagnosis and treatment of acute ischemic stroke (2014), including medical care for vital signs, control of temperature, blood pressure and glucose, improving cerebral blood circulation, antiplatelet treatment and nutritional supportive care.In addition, 25mg butylphthalide(NBP) injection, and 100ml 0.9% saline by an independent research nurse, sealed with brown bag in order to make the investigators and patients blinded, infusion for 14 days, then, butylphthalide(NBP) capsule for 76 days.

DRUG

placebo

Standard medical care is in accordance with China Guideline for the diagnosis and treatment of acute ischemic stroke (2014), including medical care for vital signs, control of temperature, blood pressure and glucose, improving cerebral blood circulation, antiplatelet treatment and nutritional supportive care.In addition, 100ml 0.9% saline by an independent research nurse, sealed with brown bag in order to make the investigators and patients blinded, infusion for 14 days, then, starch capsule for 76 days.

Trial Locations (1)

130000

First Hospital of Jilin University, Changchun

All Listed Sponsors
lead

Yi Yang

OTHER

NCT03413202 - Effectiveness of Butylphthalide on Dynamic Cerebral Autoregulation in Patients With Acute Ischemic Stroke. | Biotech Hunter | Biotech Hunter